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Abstract
Purpose Phosphate and tensin homolog (PTEN), a negative regulator of PI3K signaling, is involved in DNA repair. ATR 
is a key sensor of DNA damage and replication stress. We evaluated whether ATR signaling has clinical significance and 
could be targeted by synthetic lethality in PTEN-deficient triple-negative breast cancer (TNBC).
Methods PTEN, ATR and  pCHK1Ser345 protein level was evaluated in 1650 human breast cancers. ATR blockade by VE-821 
was investigated in PTEN-proficient- (MDA-MB-231) and PTEN-deficient (BT-549, MDA-MB-468) TNBC cell lines. 
Functional studies included DNA repair expression profiling, MTS cell-proliferation assay, FACS (cell cycle progression & 
γH2AX accumulation) and FITC-annexin V flow cytometry analysis.
Results Low nuclear PTEN was associated with higher grade, pleomorphism, de-differentiation, higher mitotic index, larger 
tumour size, ER negativity, and shorter survival (p values < 0.05). In tumours with low nuclear PTEN, high ATR and/or 
high  pCHK1ser345 level was also linked to higher grade, larger tumour size and poor survival (all p values < 0.05). VE-821 
was selectively toxic in PTEN-deficient TNBC cells and resulted in accumulation of double-strand DNA breaks, cell cycle 
arrest, and increased apoptosis.
Conclusion ATR signalling adversely impact survival in PTEN-deficient breast cancers. ATR inhibition is synthetically 
lethal in PTEN-deficient TNBC cells.
Keywords Breast cancer · Biomarker · PTEN · ATR  · Triple-negative breast cancer · Synthetic lethality
Introduction
Phosphate and tensin homolog (PTEN) is a key tumor sup-
pressor [5, 7, 14, 22]. Mutations in PTEN have been reported 
in several tumours including brain, prostrate, melanoma, 
endometrial and breast cancers. Cytoplasmic PTEN serves 
as a negative regulator of PI3K/AKT signaling pathway. 
More recently, nuclear PTEN has been shown to have roles 
in DNA repair [5, 7, 14, 22]. Ataxia telangiectasia-mutated- 
and Rad3-related protein (ATR), a serine threonine kinase 
belonging to the PIKK family (phosphoinositide 3-kinase-
like-family of protein kinase), is a critical regulator of DNA 
repair and genomic integrity [9, 10, 19, 20]. ATR can be 
activated by single stranded (ss)–double stranded (ds) DNA 
junctions generated at sites of DNA damage, during nucleo-
tide excision repair, at resected double-strand breaks and 
stalled replication forks. Activated ATR in turn phosphoryl-
ates Chk1 at  Ser345 and  Ser317, as well as several other target 
proteins involved in homologous recombination repair and 
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DNA cross-link repair. Phosphorylation of Chk1 at  Ser345 
(pChk1) leads to its activation which further coordinates cell 
cycle progression and DNA repair [9, 10, 19, 20].
In the current study, we provide evidence that ATR 
and pChk1 expression in of PTEN-deficient breast cancer 
adversely impact on survival. ATR inhibition is synthetically 
lethal in PTEN-deficient TNBC cells implying a promising 
personalized therapy approach in breast cancers.
Patients and methods
Clinical study
Patient characteristics and tissue microarray (TMA)
The Nottingham Tenovus Primary Series is a well-charac-
terized consecutive cohort of early-stage primary operable 
invasive BC patients from which the samples were used for 
the TMA construction [1, 2, 4, 21]. Patient demographics are 
summarized in Supplementary Table S1. Breast cancer spe-
cific survival (BCSS) was defined as the number of months 
from diagnosis to the occurrence of BC-related death. Sur-
vival was censored if the patient was still alive at the time of 
analysis, lost to follow-up, or died from other causes.
Immunohistochemistry (IHC)
A mouse monoclonal PTEN antibody clone 6H2.1 (Dako, 
Denmark) was diluted in 1:20 dilution using Leica Anti-
body diluent. Antigen retrieval was performed as follows: 
the TMA slides were incubated at 98 °C (in water bath) for 
25 min in target retrieval solution (pH 9.0; Leica Microsys-
tems, Newcastle, UK) then the slides were incubated for 
10 min at room temperature in warm Tris buffer saline (TBS, 
pH 7.6, 50 °C). Finally, slides were cooled by flooding in 
cold water (pH 6.0) for 5 min. The primary antibody was 
incubated for 1 h at room temperature. The Novocastra Nov-
olink Max Polymer Detection Systems (RE7280-K: 1250 
tests, Leica Biosystems) was used to visualise the staining. 
Briefly, the slides were heated at 60 °C for 10 min for dewax-
ing. Following cooling of samples to room temperature, the 
slides were rehydrated using a Leica Autostainer. After 
performing antigen retrieval, the slides were loaded onto 
Shandon Cover plates and fitted on sequenza plates for IHC. 
Initially, Endogenous peroxidase was blocked for 5 min, and 
then a protein block was applied for 5 min. The PTEN anti-
body was added, and the slides were incubated for 1 h at 
room temperature. After this, post-primary block was run 
for 30 min and then polymer was applied for further 30 min. 
The chromogen (DAB) was applied for 5 min, and tissues 
were counter-stained with haematoxylin for 6 min. Slides 
were dehydrated using Leica Autostainer and mounted with 
DPX. Negative (omission of the primary antibody) and 
positive controls were included according to manufacturer 
datasheet. ATR and pChk1 staining have been reported pre-
viously. Optimisation, specificity and cut-off points of ATR 
and pChk1 antibodies used in the current study have been 
reported previously [1]. A set of slides were incubated for 
18 h at 4 °C with the primary mouse monoclonal anti-ATR 
antibody, clone 1E9 (H00000545-M03, Novus Biologi-
cals, Cambridge, UK), at a dilution of 1:20. A further set 
of slides were incubated for 60 min with the primary rabbit 
polyclonal anti-phosphorylated Chk1 antibody (Ab58567, 
Abcam, Cambridge, UK), at a dilution of 1:140 [1].
Evaluation of immunohistochemical staining
The TMA slides were initially assessed through staining 
quality and specificity under light microscope. Slides were 
then scanned into high-resolution digital images (0.45 lm/
pixel) using a NanoZoomer slide scanner (Hamamtsu Pho-
tonics, Welwyn Garden City, UK) and accessed using a web-
based interface (Distiller, SlidePath Ltd, Dublin, Ireland). 
They were scored at ×20 magnification using a minimum of 
2400 high-resolution screen (1920 × 1080). Assessment of 
staining was based on a semi-quantitative approach using a 
modified histochemical score (H-score) taking the intensity 
of staining and the percentage of stained cells into account. 
For the intensity, a score index of 0, 1, 2, and 3 was used, 
which corresponded to negative, weak, moderate, and strong 
staining intensity, respectively. The percentage of positive 
cells per intensity was estimated. PTEN staining in breast 
tumour cells was detected in the nuclei and cytoplasm of the 
breast cancer cells. Cut-off was used to classify the tumours 
with a nuclear-PTEN H-score equal to ‘0’ as negative, and 
those with an H-score more than 0 as positive. H-score > 90 
was taken as the cut-off for high cytoplasmic-PTEN expres-
sion. Optimisation, specificity and cut-off points of ATR 
and pChk1 antibodies used in the current study have been 
reported previously [1]. H-score of ≥ 60 was taken as the 
cut-off for high ATR expression, H-score of ≥ 50 was taken 
as the cut-off for high cytoplasmic pChk1 expression and 
H-score of ≥ 50 was taken as the cut-off for high nuclear 
pChk1 expression.
Tumor marker prognostic studies (REMARK) crite-
ria, recommended by McShane et al. [13], were followed 
throughout this study. Ethical approval was obtained from 
the Nottingham Research Ethics Committee (C202313).
Statistical analysis
Statistical analysis was performed using SPSS v 22 sta-
tistical software. Association with clinical and biological 
markers was assessed using Chi-squared test. Kaplan–Meier 
survival curve with log-rank test was plotted to determine 
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the survival distribution of studied patients’ subgroups. Sta-
tistical significance was defined as p value ≤ 0.05. Due to 
multiple comparisons, the adjustment for p values of mul-
tiple testing was used according to Benjamini–Hochberg 
correction method.
Pre‑clinical study
Cell lines, tissue culture and chemical reagents
MDA-MB-231 human breast cancer cell line was purchased 
from American Type culture collection (ATCC, Manas-
sas, USA) and was grown as per ATCC recommendations. 
MDA-MB-231 cells were cultured in RPMI-1640 medium 
(Sigma, St. Louis, MO, USA) and Minimum Essential 
Medium Eagle (Sigma-Aldrich) supplemented with 1% 
l-glutamine (200 mM) and 1% non-essential amino acids 
(0.1 mM), respectively. The breast cancer cell lines BT-549 
and MDA-MB-468 (Cell Line Service, Eppelheim, Ger-
many) were cultured in Dulbecco’s Modified Eagle Medium/
Nutrient Mixture F-12 (Gibco, Carlsbad, USA). All media 
were supplemented with 10% foetal bovine serum (Sigma) 
and 1% penicillin/streptomycin (10,000 units penicillin and 
10 mg streptomycin/mL) (Sigma, Gillingham, UK). All cell 
lines were cultured as adherent cultures in a humidified 5% 
 CO2 incubator at 37 °C. ATR inhibitor (VE-821, 10 mM in 
1 mL DMSO) was purchased from Selleckchem (Houston, 
TX, USA). DMSO (Sigma, Gillingham, UK) was used as 
solvent to dissolve VE-821 and was tested solely as a vehicle 
control (< 0.1% v/v).
qRT‑PCR analysis of DNA repair gene expression in breast 
cancer cell lines
Real-time PCR was performed using  RT2 Profiler DNA 
Repair PCR Array for 84 DNA repair genes in duplicates 
as described previously [3]. The data were analyzed as per 
manufacturer’s recommendations. GAPDH was used for 
normalization of the data. A twofold change or above in 
expression was considered significant. All experiments were 
performed in duplicate.
Western blot analysis
To evaluate the specificity of PTEN-antibody used for the 
immunohistochemical study, cell lysates were prepared and 
Western blot analysis was performed. The primary anti-
bodies for PTEN, ATR, and β-actin used in this study were 
incubated at room temperature for 1 h (PTEN 1:100 dilution 
[Dako], ATR 1:1000 dilution [Cell signaling] and β-actin 
1:5000 dilution [Sigma]). Infrared dye-labelled secondary 
antibodies (Li-Cor) [IRDye 800CW Donkey Anti-Rabbit 
IgG and IRDye 680CW Donkey Anti-Mouse IgG] were 
incubated at a dilution of 1:10,000 for 1 h. Membranes were 
scanned with a Li-Cor Odyssey machine (700 and 800 nm) 
to determine protein expression.
MTS cell proliferation assay
Cells were seeded at a density of 1000 cells per well in 
96-well plates and allowed to adhere overnight. Inhibitory 
compounds were added to samples in plates at a range of 
concentrations after 16 h, followed by incubation of plates 
for total of 5 days. All steps of MTS assay were performed as 
per manufacturer’s recommendations. All experiments were 
performed in triplicate at least three times. Data analysis was 
performed in Microsoft Excel 2010 (Microsoft, Redmond, 
USA) and GraphPad Prism 6 (GraphPad, La Jolla, USA).
γH2AX accumulation and cell cycle analysis by flow 
cytometry
1 × 105 cells were seeded in 6-well tissue culture plates, 
and were allowed to adhere overnight. VE-821, an ATR 
inhibitor, was added after 16 h at the concentration of 5 μM. 
Cells were harvested by trypsinisation and centrifuged at 
1000 rpm for 5 min at 24 and 48 h post drug exposure. 
Cells pellets were then re-suspended in 1 mL of 70% ice-
cold ethanol to fix the cells. Following this, samples were 
stored at 4 °C. Suspensions were centrifuged at 1000 rpm 
for 5 min followed by removal of the supernatant. Samples 
were processed using H2AX Phosphorylation Assay Kit 
(Merckmillipore, Nottingham, UK) as per manufacturer’s 
recommendations. At least 10,000 cells from each sample 
were analysed. All experiments were done in duplicate three 
times. Weasel (Victoria, Australia) flow cytometry analysis 
software was used for data analysis. Graphical representation 
and statistical analysis was performed in GraphPad Prism 6 
(GraphPad, La Jolla, USA).
Apoptosis detection by FITC‑Annexin V flow cytometry
1 × 105 cells were seeded into 6-well tissue culture plates 
and allowed to adhere overnight. VE-821 was added to tissue 
culture plates at a concentration of 5 μM after 16 h. 24 and 
48 h after VE-821 administration. For detection of apopto-
sis, FITC-Annexin V flow cytometry was performed using 
the fluorescein isothiocyanate [FITC]-Annexin V Apoptosis 
Detection Kit I (BD Pharmingen, San Jose, USA) as per 
manufacturer’s recommendations. At least 10,000 cells from 
each sample were analysed. Weasel (Victoria, Australia) 
flow cytometry analysis software was used for data analysis. 
The percentage of apoptotic cells (FITC-Annexin V positive, 
PI positive and FITC-Annexin V positive, PI negative) in 
the treated population was ascertained by comparing it to a 
control population of untreated samples. Statistical analysis 
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was performed in GraphPad Prism 6 (GraphPad, La Jolla, 
USA). All experiments were done in duplicate three times.
Results
Loss of nuclear PTEN and aggressive breast cancers
The loss of nuclear PTEN expression was observed in 
508/811 (62.6%) tumours compared with 303/811 (37.4%) 
Fig. 1  a Nuclear and cytoplasmic staining of PTEN [a negative stain-
ing for both, b negative staining for nuclei and weak for cytoplasm, c 
some weak staining for nuclei and moderate for cytoplasm d strong 
staining for both; TMA cores pictures were taken using digital pathol-
ogy interference at ×100 (left) and ×200 (right)]. Kaplan–Meier plot 
showing breast cancer-specific survival (BCSS) and b nuclear PTEN 
level. c combined nuclear PTEN and ATR level. d combined nuclear 
PTEN and cytoplasmic pCHK1 level. e combined ATR and cytoplas-
mic pCHK1 level nuclear PTEN negative tumours
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tumours which had positive expression of nuclear (PTEN). 
Low cytoplasmic PTEN expression was seen in 326/811 
(40.2%) tumours compared with the 485/811 (59.8%) 
tumours which had high cytoplasmic expression (Fig. 1a). 
The negative nuclear PTEN was associated with higher 
grade, less tubule formation, pleomorphism, higher mitotic 
index, larger tumour size, high-risk Nottingham Prognostic 
Index (NPI), ER− and PR− tumours (all adjusted p val-
ues < 0.01) (Table 1). Similarly, low cytoplasmic PTEN was 
also associated with aggressive phenotype including high 
grade, de-differentiation, higher mitotic index and larger 
tumours (all adjusted p values < 0.005) (Table 2).
PTEN, ATR, and  pChk1ser345 co‑expression 
and survival
A previous preclinical study has shown that loss of PTEN 
and activation of AKT can impair Chk1 through phospho-
rylation, reduce nuclear localization, promote cytoplasmic 
Table 1  Association between nuclear-PTEN expression and clinico-
pathological variables
Bold = statistically significant result
Parameters Negative 
(%)
Positive (%) p value Adjusted p 
value
Grade 2.2 × 10−7 1.6 × 10−6
 1 49 (9.7) 55 (18.3)
 2 149 (29.6) 122 (40.5)
 3 305 (60.6) 124 (41.2)
Tubules 0.001553 0.0021742
 1 20 (4.1) 17 (5.8)
 2 144 (29.3) 118 (40.4)




 1 8 (1.6) 5 (1.7)
 2 154 (31.4) 131 (44.9)
 3 329 (67.0) 156 (53.4)
Mitosis 0.000001 0.0000035
 1 123 (25.0) 121 (41.4)
 2 94 (19.1) 59 (20.2)
 3 275 (55.9) 112 (38.4)
Stage 0.475148 3.3250
 I 294 (58.4) 189 (62.8)
 II 167 (33.2) 89 (29.6)
 III 42 (8.3) 23 (7.6)
Tumour size 0.020606 0.024040333
 < 2.0 218 (43.3) 156 (51.7)
 ≥ 2.0 286 (56.7) 146 (48.3)
NPI 0.000012 0.000028
 > 0.3 107 (22.3) 109 (37.8)
 3.4–5.4 291 (60.6) 147 (51.0)
 > 5.4 82 (17.1) 32 (11.1)
ER status 8.6 × 10−11 2.5 × 10−10
 Negative 175 (34.8) 42 (13.9)
 Positive 328 (65.2) 261 (86.1)
PR status 8 × 10−11 4.8 × 10−10
 Negative 251 (51.6) 82 (27.9)
 Positive 235 (48.4) 212 (72.1)
HER2 status 0.512577 0.6150924
 Negative 412 (84.6) 241 (82.8)
 Positive 75 (15.4) 50 (17.2)
Table 2  Association between cytoplasmic-PTEN expression and clin-
icopathological variables
Bold = statistically significant result
Parameters Low (%) High (%) P value Adjusted p value
Grade 0.002740 0.006393333
 1 27 (8.3) 77 (16.0)
 2 107 (33.0) 164 (34.2)
 3 190 (58.6) 239 (49.8)
Tubules 0.000169 0.001183
 1 9 (2.9) 28 (6.0)
 2 84 (26.7) 178 (38.0)
 3 222 (70.5) 263 (56.1)
Pleomorphism 0.991045 6.937315
 1 5 (1.6) 8 (1.7)
 2 114 (36.3) 171 (36.5)
 3 195 (62.1) 290 (61.8)
Mitosis 0.000455 0.0015925
 1 85 (27.0) 159 (33.9)
 2 48 (15.2) 105 (22.4)
 3 182 (57.8) 205 (43.7)
Stage 0.466340 0.544063333
 I 203 (62.7) 280 (58.3)
 II 96 (29.6) 160 (33.3)
 III 25 (7.7) 40 (8.3)
Tumour size 0.012480 0.017472
 < 2.0 133 (41.0) 241 (50.0)
 ≥ 2.0 191 (59.0) 241 (50.0)
NPI 0.003111 0.00544425
 > 0.3 69 (22.4) 147 (32.0)
 3.4–5.4 198 (64.3) 240 (52.2)
 > 5.4 41 (13.3) 73 (15.9)
ER status 0.000004 0.000012
 Negative 115 (35.7) 102 (21.1)
 Positive 207 (64.3) 382 (78.9)
PR status 0.000319 0.0004785
 Negative 158 (50.5) 175 (37.5)
 Positive 155 (49.5) 292 (62.5)
HER2 status 0.000008 0.000016
 Negative 286 (91.1) 367 (79.1)
 Positive 28 (8.9) 97 (20.9)
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sequestration, ubiquitination and degradation [18]. Loss of 
nuclear PTEN can also promote genomic instability and 
DNA strand breaks which can activate ATR. We, therefore, 
investigated PTEN, ATR, and  pChk1ser345 co-expression in 
clinical breast cancers. A strong association between nega-
tive nuclear PTEN and negative nuclear pChk1 expression 
was observed. Interestingly, there was also a significant asso-
ciation between low cytoplasmic PTEN and low ATR as 
well low-cytoplasmic Chk1 expression (Table 3). We then 
proceeded to evaluate prognostic significance of PTEN, 
ATR, and  pChk1ser345 co-expression.
The nuclear PTEN negativity was associated with shorter 
breast cancer-specific survival (BCSS) (p = 0.005) compared 
to nuclear PTEN-positive breast cancer (Fig. 1b). In contrast 
cytoplasmic PTEN did not influence survival (Supplemen-
tary Fig. S1A). When combined together, we observed that 
tumours with nuclear PTEN-negative/cytoplasmic PTEN-
positive tumours had the worst BCSS (p = 0.039) (Supple-
mentary Fig. S1B).
We then investigated the prognostic significance of 
PTEN, ATR and  pChk1ser345 co-expression in patients. 
Nuclear PTEN negative/high ATR tumours were associated 
with the worst BCSS (p = 0.029) (Fig. 1c). Similarly, nuclear 
PTEN-negative/high-cytoplasmic  pCHK1ser345 tumours were 
associated with poor survival (p = 0.031) (Fig. 1d). Nuclear 
PTEN-negative/high-nuclear  pCHK1ser345 tumours were also 
associated with poor survival (p = 0.037) (Supplementary 
Fig. 1c). In nuclear PTEN-negative tumours, we then inves-
tigated the prognositic significance of ATR- cytoplasmic 
 pCHK1ser345 co-expression. As shown in Fig. 1e, tumours 
with high-ATR and -cytoplasmic  pCHK1ser345 expression 
had the worst survival compared to those with low-ATR and-
cytoplasmic expression (p = 0.014).
ATR and/or  pCHK1ser345 did not influence survival in 
tumours with low- or high-cytoplasmic PTEN expression 
(Supplementary Fig. S1D–S1G).
Taken together, the clinical data suggest that nuclear 
PTEN deficiency as well as ATR and  pChk1ser345 expres-
sion in nuclear PTEN-deficient breast cancers is associated 
with aggressive breast cancers.
PTEN‑deficient breast cancer cell lines demonstrate 
deregulation in gene expression of multiple DNA 
repair pathways
We initially screened a panel of TNBC cell lines for expres-
sion of PTEN, ATR, total Chk1 and  pChk1ser345. As shown 
in Fig. 2a, MDA-MB-231 cell line is PTEN-proficient, 
Table 3  Association between PTEN, ATR and pChk1expression in breast cancers







Unadjusted p value Adjusted p value
ATR 0.736306 4.417836
 Negative 87 (36.6) 57 (38.3)
 Positive 151 (63.4) 92 (61.7)
Nuclear pChk1 5.3 × 10−8 1.1 × 10−7
 Negative 294 (63.5) 122 (43.1)
 Positive 169 (36.5) 161 (56.9)
Cytoplasmic pChk1 0.002627 0.0039405
 Negative 127 (30.2) 51 (19.8)







Unadjusted p value Adjusted p value
ATR 0.005322 0.0063864
 Negative 66 (46.2) 78 (32.0)
 Positive 77 (53.8) 166 (68.9)
Nuclear pChk1 0.396997 2.381982
 Negative 169 (57.7) 247 (54.5)
 Positive 124 (42.3) 206 (45.5)
Cytoplasmic pChk1 8.2 × 10−7 4.9 × 10−6
 Negative 96 (36.8) 82 (19.7)
 Positive 165 (63.2) 335 (80.3)
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whereas BT-549 and MDA-MB-468 cell lines are PTEN 
deficient. We did not observe any significant differences in 
the expression of ATR in MDA-MB-231, BT-549 and MDA-
MB-468 TNBC cell lines (Fig. 2a). Previous studies suggest 
that nuclear PTEN may have roles in DNA repair includ-
ing in homologous recombination repair. To test whether 
BT-549 and MDA-MB-468 cells have altered DNA repair 
expression compared to MDA-MB-231 cells, we profiled 
the mRNA level expression of 84 DNA repair genes using 
the  RT2-Profiler DNA Repair PCR array. The expression of 
DNA repair genes in BT-549 and MDA-MB-468 cells was 
compared with DNA repair expression in MDA-MB-231. 
The data are shown in Fig. 2b, c as well as in Supplementary 
Tables S2–S7. We observed more than two-fold downregula-
tion of several genes in HR, BER, NHEJ, MMR and NER. 
Interestingly, in MDA-MB-468, we observed upregulation of 
PARP2, XRCC6BP1, LIG1, RPA3 and MGMT. In BT-549 
cells, DMC1, XRCC6BP1 and MGMT were significantly 
upregulated. The data would not only concur with previously 
published data but also support the hypothesis that PTEN 
deficiency can alter DNA repair expression status in cells.
VE‑821 (ATR inhibitor) is selectively toxic in PTEN 
deficient TNBC cells
Given the current pharmaceutical interest in the devel-
opment of ATR inhibitors for cancer therapy, we pre-
clinically tested whether ATR inhibition could be selec-
tively toxic in PTEN-deficient cells. VE-821 is a highly 
selective ATR kinase inhibitor with an  IC50 of 26 nM in 
cell-free assays for ATR inhibition. In MTS cell prolifera-
tion assays, we observed that VE-821 was more toxic to 
BT-549 and MDA-MB-468 compared to MDA-MB-231 
cells (Fig. 2d).
Phosphorylated H2AX (γH2AX) is a marker of double-
strand breaks. As expected, there was substantial γH2AX 
Fig. 2  a Western blotting analysis for PTEN, ATR expression in 
breast cancer cell lines. b DNA repair expression profiling in BT549 
cells compared to MDA-MB-231 cells. c DNA repair expression 
profiling in MDA-MB-468 cells compared to MDA-MB-231 cells. 
d MTS growth inhibition assay in a panel of PTEN-proficient and—
deficient human BC cells treated with VE-821. e γH2AX accumula-
tion by FACS in BC cells treated with VE821
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accumulation [thereby suggesting double-strand break 
(DSBs) accumulation] in BT-549 and MDA-MB-468 cells 
compared to MDA-MB-231 cells after 24 h of VE-821 
treatment (Fig. 2E1, E2). The accumulation of DSBs was 
associated with S-phase arrest in BT-549 cells and G2/M 
arrest in MDA-MB-468 cells after 48 h of VE-821 treat-
ment (Figs. 3A1, 3A2). Cell cycle arrest was subsequently 
followed by accumulation of apoptotic cells (Figs. 3B1, 
2B2).
Taken together, the data provides evidence that VE-821 
induces synthetic lethality in PTEN-deficient cells through 
accumulation of DSBs, cell cycle arrest and induction of 
apoptosis.
Discussion
We provide the first clinical evidence that ATR signaling 
could have adverse impact on survival in PTEN-deficient 
breast cancers. In addition, the pre-clinical evidence pre-
sented here also suggests that ATR inhibition could be a 
promising synthetic lethality strategy in PTEN-deficient 
breast cancers.
Loss of not only cytoplasmic PTEN expression but also 
nuclear PTEN expression was associated with aggressive 
ER−, PR− and HER2− phenotypes. Our data concurs with 
previous studies that correlate PTEN loss with TNBCs [6, 
8, 16]. In addition, the negative PTEN expression status 
either in cytoplasm or nucleus resulted in negative expres-
sion of nuclear or cytoplasmic  pCHK1ser345. The data are 
Fig. 3  a Cell cycle analysis by FACS in BC cells treated with VE821. b Apoptosis detection by Annexin V-FITC FACS in BC cells treated with 
VE821
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consistent with a previous study showing that the loss of 
PTEN-impaired Chk1 through phosphorylation mediated 
by elevated AKT and subsequent Chk1 ubiquitination 
[18]. Puc et al. also demonstrated that PTEN loss reduces 
Chk1 nuclear localization, thereby increasing the genomic 
instability and promoting tumorigenesis [18]. Supporting 
these observations, our study demonstrated that cytoplas-
mic/nuclear PTEN loss resulted in significantly increasing 
tumour size, mitotic index and NPI.
Whereas cytoplasmic PTEN serves as a negative regula-
tor of PI3K/AKT signaling, nuclear PTEN has been shown 
to have roles in DNA repair [5, 7, 14, 22]. For example, 
PTEN loss has been shown to trigger downregulation of 
both RAD51 [15, 23] and BRCA1 [17]. Accordingly, we 
observed that DNA repair profiling in PTEN-deficient cells, 
altered expression of several genes involved multiple DNA 
repair pathways including BER, NHEJ, HR, NER and MMR. 
The data suggest that PTEN may be directly or indirectly 
involved in the regulation of multiple DNA repair genes.
Pharmaceutical development of ATR inhibitors for can-
cer therapy is an attractive anti-cancer strategy [9, 10]. Pre-
clinically, we observed that PTEN deficient breast cancer 
cells were sensitive to ATR inhibition and was associated 
with accumulation of DSBs, cell cycle arrest and induction 
of apoptosis. The data imply that PTEN-deficient cells with 
impaired DNA repair may be reliant upon ATR signaling 
pathway for survival. ATR blockade in this context could 
lead to synthetic lethality. Recently, ATM inhibition was 
also shown to be synthetically lethal in PTEN-deficient cells 
[12]. Interestingly, ATM-deficient cells are also sensitive to 
ATR inhibitors via synthetic lethality in leukemic cells [11].
In conclusion, we have demonstrated that ATR signaling 
adversely impact upon survival in PTEN-deficient breast 
cancers. ATR targeting could be a promising synthetic 
lethality approach in PTEN-deficient breast cancers.
Acknowledgements A part of this work was supported by Breast Can-
cer Now (Grant Number: 2015MaySP537).
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Abdel-Fatah TM et  al (2015) Untangling the ATR-CHEK1 
network for prognostication, prediction and therapeutic target 
validation in breast cancer. Mol Oncol 9:569–585. https ://doi.
org/10.1016/j.molon c.2014.10.013
 2. Abdel-Fatah TM et al (2014) DNA polymerase beta deficiency 
is linked to aggressive breast cancer: a comprehensive analysis 
of gene copy number, mRNA and protein expression in multiple 
cohorts. Mol Oncol 8:520–532. https ://doi.org/10.1016/j.molon 
c.2014.01.001
 3. Albarakati N et al (2015) Targeting BRCA1-BER deficient breast 
cancer by ATM or DNA-PKcs blockade either alone or in combi-
nation with cisplatin for personalized therapy. Mol Oncol 9:204–
217. https ://doi.org/10.1016/j.molon c.2014.08.001
 4. Arora A et al (2015) Transcriptomic and protein expression analy-
sis reveals clinicopathological significance of bloom syndrome 
helicase (BLM) in breast cancer. Mol Cancer Ther 14:1057–1065. 
https ://doi.org/10.1158/1535-7163.MCT-14-0939
 5. Bassi C et al (2013) Nuclear PTEN controls DNA repair and 
sensitivity to genotoxic stress. Science 341:395–399. https ://doi.
org/10.1126/scien ce.12361 88
 6. Bose S et al (2002) Reduced expression of PTEN correlates with 
breast cancer progression. Hum Pathol 33:405–409
 7. Chalhoub N, Baker SJ (2009) PTEN and the PI3-kinase pathway 
in cancer. Annu Rev Pathol 4:127–150. https ://doi.org/10.1146/
annur ev.patho l.4.11080 7.09231 1
 8. Depowski PL et al (2001) Loss of expression of the PTEN gene 
protein product is associated with poor outcome in breast can-
cer. Mod Pathol 14:672–676. https ://doi.org/10.1038/modpa 
thol.38803 71
 9. Fokas E et al (2014) Targeting ATR in DNA damage response 
and cancer therapeutics. Cancer Treat Rev 40:109–117. https ://
doi.org/10.1016/j.ctrv.2013.03.002
 10. Karnitz LM, Zou L (2015) Molecular Pathways: targeting ATR 
in Cancer Therapy. Clin Cancer Res 21:4780–4785. https ://doi.
org/10.1158/1078-0432.CCR-15-0479
 11. Kwok M et al (2016) ATR inhibition induces synthetic lethal-
ity and overcomes chemoresistance in TP53- or ATM-defective 
chronic lymphocytic leukemia cells. Blood 127:582–595. https ://
doi.org/10.1182/blood -2015-05-64487 2
 12. McCabe N et al (2015) Mechanistic rationale to target PTEN-
deficient tumor cells with inhibitors of the DNA damage 
response kinase ATM. Cancer Res 75:2159–2165. https ://doi.
org/10.1158/0008-5472.CAN-14-3502
 13. McShane LM et  al (2005) Reporting recommendations for 
tumor marker prognostic studies (REMARK). J Natl Cancer Inst 
97:1180–1184. https ://doi.org/10.1093/jnci/dji23 7
 14. Ming M, He YY (2012) PTEN in DNA damage repair. Cancer 
Lett 319:125–129. https ://doi.org/10.1016/j.canle t.2012.01.003
 15. Mukherjee A, Karmakar P (2013) Attenuation of PTEN perturbs 
genomic stability via activation of Akt and down-regulation of 
Rad51 in human embryonic kidney cells. Mol Carcinog 52:611–
618. https ://doi.org/10.1002/mc.21903 
 16. Perren A et al (1999) Immunohistochemical evidence of loss 
of PTEN expression in primary ductal adenocarcinomas of the 
breast. Am J Pathol 155:1253–1260. https ://doi.org/10.1016/
S0002 -9440(10)65227 -3
 17. Phuah SY et al (2012) Triple-negative breast cancer and PTEN 
(phosphatase and tensin homologue) loss are predictors of BRCA1 
germline mutations in women with early-onset and familial breast 
cancer, but not in women with isolated late-onset breast cancer. 
Breast Cancer Res 14:R142. https ://doi.org/10.1186/bcr33 47
 18. Puc J et al (2005) Lack of PTEN sequesters CHK1 and initi-
ates genetic instability. Cancer Cell 7:193–204. https ://doi.
org/10.1016/j.ccr.2005.01.009
 19. Saldivar JC et al (2017) The essential kinase ATR: ensuring faith-
ful duplication of a challenging genome. Nat Rev Mol Cell Biol 
18:622–636. https ://doi.org/10.1038/nrm.2017.67
 20. Smits VA et al (2010) Mechanisms of ATR-mediated checkpoint 
signalling. Front Biosci 15:840–853
 Breast Cancer Research and Treatment
1 3
 21. Sultana R et al (2013) Targeting XRCC1 deficiency in breast can-
cer for personalized therapy. Cancer Res 73:1621–1634. https ://
doi.org/10.1158/0008-5472.CAN-12-2929
 22. Worby CA, Dixon JE (2014) Pten. Annu Rev Biochem 83:641–
669. https ://doi.org/10.1146/annur ev-bioch em-08241 1-11390 7
 23. Zhao Q et al (2017) Inhibition of Rad51 sensitizes breast cancer 
cells with wild-type PTEN to olaparib. Biomed Pharmacother 
94:165–168. https ://doi.org/10.1016/j.bioph a.2017.07.090
